AVANOS MEDICAL (AVNS) Expected to Announce Quarterly Earnings on Wednesday

by · The Cerbat Gem

AVANOS MEDICAL (NYSE:AVNS – Get Free Report) will likely be releasing its Q3 2025 results before the market opens on Wednesday, October 29th. Analysts expect AVANOS MEDICAL to post earnings of $0.19 per share and revenue of $164.50 million for the quarter. AVANOS MEDICAL has set its FY 2025 guidance at 0.750-0.950 EPS.Parties can find conference call details on the company’s upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Wednesday, November 5, 2025 at 9:00 AM ET.

AVANOS MEDICAL (NYSE:AVNS – Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The company reported $0.17 EPS for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.01). AVANOS MEDICAL had a positive return on equity of 6.16% and a negative net margin of 66.89%.The company had revenue of $175.00 million for the quarter, compared to analyst estimates of $165.50 million. During the same period in the prior year, the firm posted $0.34 earnings per share. On average, analysts expect AVANOS MEDICAL to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

AVANOS MEDICAL Stock Down 0.7%

AVNS stock opened at $11.71 on Tuesday. The company’s 50 day moving average price is $11.76 and its 200 day moving average price is $11.98. The firm has a market capitalization of $543.44 million, a price-to-earnings ratio of -1.16 and a beta of 1.15. AVANOS MEDICAL has a fifty-two week low of $9.30 and a fifty-two week high of $22.86. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.58 and a current ratio of 2.64.

Insider Activity

In related news, Director Gary Blackford bought 40,000 shares of the stock in a transaction dated Wednesday, August 13th. The stock was acquired at an average price of $10.99 per share, for a total transaction of $439,600.00. Following the acquisition, the director owned 40,000 shares in the company, valued at approximately $439,600. This represents a ∞ increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 2.64% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in AVNS. Russell Investments Group Ltd. lifted its stake in AVANOS MEDICAL by 969.3% in the second quarter. Russell Investments Group Ltd. now owns 2,545 shares of the company’s stock valued at $31,000 after buying an additional 2,307 shares during the last quarter. Tower Research Capital LLC TRC increased its holdings in shares of AVANOS MEDICAL by 433.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,257 shares of the company’s stock valued at $77,000 after acquiring an additional 5,083 shares during the period. State of Wyoming increased its holdings in shares of AVANOS MEDICAL by 64.4% in the 2nd quarter. State of Wyoming now owns 17,273 shares of the company’s stock valued at $211,000 after acquiring an additional 6,765 shares during the period. Cerity Partners LLC purchased a new stake in AVANOS MEDICAL in the 2nd quarter valued at $272,000. Finally, Quantinno Capital Management LP boosted its stake in AVANOS MEDICAL by 131.9% during the 2nd quarter. Quantinno Capital Management LP now owns 27,212 shares of the company’s stock worth $333,000 after purchasing an additional 15,479 shares during the period. Institutional investors and hedge funds own 95.17% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have commented on the stock. Wall Street Zen downgraded shares of AVANOS MEDICAL from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of AVANOS MEDICAL in a research note on Tuesday, October 14th. Finally, Zacks Research upgraded AVANOS MEDICAL to a “hold” rating in a research note on Tuesday, August 12th. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Reduce”.

Read Our Latest Stock Report on AVNS

About AVANOS MEDICAL

(Get Free Report)

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.

Featured Stories